T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024

GlobeNewswire04-24

LEXINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the first quarter 2024 and business updates after market close on Monday, May 6, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International), passcode 160751, approximately ten to five minutes prior to the start time.

About T2 Biosystems

T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx^® Instrument, the T2Bacteria^® Panel, the T2Candida^® Panel, the T2Resistance^® Panel, and the T2Biothreat™ Panel, and are powered by the proprietary T2 Magnetic Resonance (T2MR^®) technology. T2 Biosystems has an active pipeline of future products, including the U.S. T2Resistance Panel, the Candida auris test, and the T2Lyme™ Panel. For more information, please visit www.t2biosystems.com.

Investor Contact:
Philip Trip Taylor, Gilmartin Group
ir@T2Biosystems.com
415-937-5406

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2429455394?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-24 13:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2429455394","market":"hk","top_or_hot":-1,"title":"T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024","media":"GlobeNewswire","content":"<html><body><p>LEXINGTON, Mass., April  24, 2024  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/TTOO\">T2 Biosystems</a>, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the first quarter 2024 and business updates after market close on Monday, May 6, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.<br/></p> <p>Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events &amp; Presentations section. To listen to the conference call, please dial 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International), passcode 160751, approximately ten to five minutes prior to the start time.</p> <p><strong>About T2 Biosystems</strong></p> <p>T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx<sup>®</sup> Instrument, the T2Bacteria<sup>®</sup> Panel, the T2Candida<sup>®</sup> Panel, the T2Resistance<sup>®</sup> Panel, and the T2Biothreat™ Panel, and are powered by the proprietary T2 Magnetic Resonance (T2MR<sup>®</sup>) technology. T2 Biosystems has an active pipeline of future products, including the U.S. T2Resistance Panel, the <em>Candida auris</em> test, and the T2Lyme™ Panel. For more information, please visit www.t2biosystems.com.</p> <p><strong>Investor Contact:</strong><br/>Philip Trip Taylor, Gilmartin Group<br/>ir@T2Biosystems.com<br/>415-937-5406</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/MzBlNGYyNGItNTY3Yi00MTY0LTkxMDgtNzBmZjM5MzEzYmE3LTEwMTc0MTc=/tiny/T2-Biosystems-Inc-.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nT2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-24 13:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.globenewswire.com/news-release/2024/04/24/2868659/32489/en/T2-Biosystems-to-Report-First-Quarter-2024-Financial-Results-and-Business-Updates-on-May-6-2024.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>LEXINGTON, Mass., April  24, 2024  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today ...</p>\n\n<a href=\"https://www.globenewswire.com/news-release/2024/04/24/2868659/32489/en/T2-Biosystems-to-Report-First-Quarter-2024-Financial-Results-and-Business-Updates-on-May-6-2024.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4583","symbol_name":"猴痘概念","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2024/04/24/2868659/32489/en/T2-Biosystems-to-Report-First-Quarter-2024-Financial-Results-and-Business-Updates-on-May-6-2024.html","article_id":"2429455394","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2429455394","pubTimestamp":1713934800,"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"LEXINGTON, Mass., April  24, 2024  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO),a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today th","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4583":"猴痘概念","TTOO":"T2 Biosystems","BK4139":"生物科技"},"translate_title":"T2生物系统公司将于2024年5月6日报告2024年第一季度财务业绩和业务更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TTOO":1},"content_text":"LEXINGTON, Mass., April  24, 2024  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the first quarter 2024 and business updates after market close on Monday, May 6, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International), passcode 160751, approximately ten to five minutes prior to the start time. About T2 Biosystems T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel, and the T2Biothreat™ Panel, and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the U.S. T2Resistance Panel, the Candida auris test, and the T2Lyme™ Panel. For more information, please visit www.t2biosystems.com. Investor Contact:Philip Trip Taylor, Gilmartin Groupir@T2Biosystems.com415-937-5406","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2429455394"}